You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆指升幅擴至逾300點 醫藥股普遍造好 金斯瑞(01548.HK)及艾美(06660.HK)升6%至8%
恆指今日(11日)午後在新經濟股主導,升幅擴大至339點或2.1%,現報16,437,總成交額547億元。 醫藥板塊今天普遍隨大市造好。藥明系全面受捧,藥明康德(02359.HK)、藥明合聯(02268.HK)及上調今年藥物開發目標的藥明生物(02269.HK)股價曾漲逾9%至19%後遇壓,現升幅收窄至近6%至11%;藥明生物現報31元,續升10.7%。 CXO板塊H股同業亦隨A股走高,泰格醫藥(03347.HK)及康龍化成(03759.HK)漲4.7%至6.1%、昭衍新藥(06127.HK)亦升近3%。 近期獲主席頻頻增持的艾美疫苗(06660.HK),也由低位連升第三天,今天升覆高見8.25元,現報7.94元,續漲7.7%。 金斯瑞生物(01548.HK)由低位連升第三天兼重越10天線,最高見18.94元,現報18.84元,續升逾6%。 君實生物(01877.HK)、開拓藥業-B(9939.HK)、和鉑醫藥-B(02142.HK)、雲頂新耀-B(01952.HK)、神威藥業(02877.HK)、來凱醫藥-B(02105.HK)、維亞生物(01873.HK)及藍籌國藥(01099.HK)升逾2%至4%。另藍籌中生製藥(01177.HK)、石藥(01093.HK)、翰森製藥(03692.HK)亦升0.7%至1.5%。 線上醫藥股同造好,平安好醫生(01833.HK)升1.2%、藍籌阿里健康(00241.HK)及京東健康(06618.HK)漲2.5%至3.3%。 相反,百濟神州(06160.HK)三連升後受制50天線,今天股價曾回吐5.3%低見104.6元,現報106.9元,回吐逾3%。再鼎醫藥(09688.HK)重失10天線(20.8元),最低見20.1元,現報20.55元,回吐逾2%。聯邦制藥(03933.HK)、康方生物(09926.HK)及綠葉製藥(02186.HK)各回吐逾1%至2%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account